» btjax8f6

セラノスティクス横浜がお届けする最新のセラノスティクス　セラヨコ・ライブラリー

Information
2025.03.24　
サイトを公開しました。

文献のご紹介　※セラヨコ・トーク付き

Prognostic and predictive value of baseline PSMA-PETtotal tumour volume and SUVmean in metastatic castrationresistant prostate cancer in ENZA-p (ANZUP1901): a substudyfrom a multicentre, open-label, randomised, phase 2 trial

DOI: 10.1016/
S1470-2045(25)00339-0

The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from anEntire Country

DOI: 10.2967/
jnumed.125.269996

Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

DOI: 10.2967/
jnumed.124.269431

Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT

DOI: 10.2967/
jnumed.124.268071

First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/ll study.

Journal of Clinical Oncology • Volume 43, Number 16 suppl
DOI　10.1200/
JCO.2025.43.16_suppl.5010

PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease

Woo et al. European Radiology
DOI　10.1007/
s00330-025-11514-3

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on (“8Ga]Ga-PSMA-11 PET/CT in the proPSMA Study

J Nucl Med 2025; 66:713-718
DOI　10.2967/
jnumed.124.268901

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Journal of Nuclear Medicine September 2024, jnumed.124.268020;
DOI 10.2967/
jnumed.124.268020

1 2 3 次へ »

※セラヨコ・トーク＝抄読会でのセラヨコメンバーのつぶやき

動画コンテンツ